Shandong Realcan Pharmaceutical Co Ltd

Realcan Pharmaceutical Group Co., Ltd. sells medicines, medical devices, and medical consumables to medical institutions in China. It operates through the Drug and Equipment Distribution, In Vitro Diagnostics, Pharmaceutical Logistics, Traditional Chinese Medicine, and Microbiome Medicine segments. The company also engages in the processing, manufacture, sale, and wholesale of Chinese medicinal materials, herbal medicine, and patent medicine, as well as the wholesale of biochemical, psychotropic, narcotic, and toxic drugs for medical use, chemical APIs and preparations, antibiotics, biological products, anabolic steroids, peptide hormones, and pharmaceutical precursor chemicals, and medical devices. In addition, it provides leasing of medical devices and technical services, investment management and consulting services, medical sterilization outsourcing and consulting services, health consulting services, and pharmaceutical logistics services, and is involved in the warehousing and distribution of drugs, technology development and transfer, and operation of a health service platform. The company was formerly known as Realcan Pharmaceutical Co., Ltd. and changed its name to Realcan Pharmaceutical Group Co., Ltd. in December 2018. It was founded in 2004 and is based in Yantai, China.

002589.CS▼

Ruikang Pharmaceutical's 2026 Interim Net Profit Falls 38.70% Year on Year

Ruikang Pharmaceutical released its 2026 interim report, with net profit attributable to the parent company of 11.1353 million yuan, down 38.70% from the same period last year. Total operating revenue was 3.415 billion yuan, down 3.63% year on year. Net cash inflow from operating activities was 48.7179 million yuan, down 28.24% year on year. The company's latest asset-liability ratio was 65.82%, gross margin was 11.37%, return on equity was 0.21%, and diluted earnings per share was 0.01 yuan.

002589.CS ▼

Jiemian·28dRead more →